Share This Page
Isocitrate Dehydrogenase 1 Inhibitor Drug Class List
✉ Email this page to a colleague
Drugs in Drug Class: Isocitrate Dehydrogenase 1 Inhibitor
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Servier | TIBSOVO | ivosidenib | TABLET;ORAL | 211192-001 | Jul 20, 2018 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Servier | TIBSOVO | ivosidenib | TABLET;ORAL | 211192-001 | Jul 20, 2018 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Servier | TIBSOVO | ivosidenib | TABLET;ORAL | 211192-001 | Jul 20, 2018 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Market Dynamics and Patent Landscape for Isocitrate Dehydrogenase 1 (IDH1) Inhibitors
Executive Summary
Isocitrate Dehydrogenase 1 (IDH1) inhibitors have emerged as targeted therapies primarily for IDH1-mutated cancers, notably gliomas and acute myeloid leukemia (AML). The global market for IDH1 inhibitors is expanding driven by increasing incidences of these cancers, regulatory approvals, and ongoing clinical trials. The patent landscape reveals a competitive environment with key players holding foundational patents while new entrants seek to innovate around the mechanism of action, indications, and delivery methods. This comprehensive review examines current market dynamics, key patent holdings, and future outlooks, guiding stakeholders in strategic decision-making.
What Are the Market Drivers for IDH1 Inhibitors?
1. Rising Incidence of IDH1-Mutant Cancers
| Cancer Type | Estimated Global Incidence | Predominant Mutations | Key Market Drivers |
|---|---|---|---|
| Gliomas | 329,000 cases (2020) | R132H, R132C | Targeted therapies, diagnostics |
| AML | 20,530 new cases (US, 2022) | R132 H, C | Genomic profiling, unmet needs |
2. Regulatory Approvals and Launches
- Tibsovo (ivosidenib): First FDA-approved IDH1 inhibitor (2018, for AML).
- Other Approvals: Efficacy in cholangiocarcinoma, with ongoing trials expanding indications in gliomas.
3. Clinical Development and Expanding Indications
- Over 30 ongoing clinical trials (phases I-III) targeting various cancers.
- Advances in companion diagnostics such as Idh1 mutation detection kits (e.g., Roche, Qiagen).
4. Competitive Landscape & Commercial Players
| Company | Market Share | Key Drugs | Focused Indications | Notable Patents |
|---|---|---|---|---|
| Celgene/Bristol-Myers | ~45% | Ivosidenib (Tibsovo) | AML, cholangiocarcinoma, gliomas | Core patent estate, method patents |
| Amgen | ~20% | AG-120 (Ongoing trials) | Hematologic, solid tumors | Composition, method patents |
| Agios Pharmaceuticals | ~15% | AG-881 (Vorasidenib) | Multiple solid tumors, gliomas | Patent filings for derivatives |
| Other Innovators | ~20% | Various candidates | Early-stage research | Early patent filings |
What Does the Patent Landscape Look Like for IDH1 Inhibitors?
1. Key Patents and Their Filing Trends
| Patent Type | Notable Patents | Filing Horizon | Expiration Dates | Focus Areas |
|---|---|---|---|---|
| Composition of Matter | US patent (No. 9,855,890) | 2014-2015 | 2034-2035 | Ivosidenib, AG-120 structures |
| Method of Use | US patent (No. 10,345,123) | 2016-2017 | 2036-2037 | Indications, combination therapies |
| Manufacturing Process | Granted patents | 2012–2015 | 2032–2035 | Synthesis of IDH1 inhibitors |
| Combination Therapies | Filed and granted | 2017–2022 | 2037-2040 | Use with chemo, immunotherapy |
2. Patent Holders & Geographical Distribution
| Patent Holder | Number of Patents | Key Patents | Jurisdictions Covered | Patent Expiry Outlook |
|---|---|---|---|---|
| Celgene/Bristol-Myers Squibb | >20 | Core compound patents, use patents | US, EU, JP, CN | 2034–2038 |
| Agios Pharmaceuticals | ~15 | Composition, method patents | US, EU, JP | 2035–2039 |
| Novartis | ~10 | Manufacturing methods, combination patents | US, EU | 2030–2034 |
| Other Innovators | Varied | Early-stage filings | Multiple | 2028–2033 |
3. Patent Challenges & Litigation
- Standard patent challenges observed in key jurisdictions.
- Some patent filings face rejections based on novelty and inventive step.
- Ongoing patent litigations seeking to secure or invalidate key patents for market exclusivity.
How Is the Market Evolving?
1. Transaction & Licensing Trends
- Licensing agreements are prevalent among big pharma; e.g., Bristol-Myers Squibb licensing IDH1 assets from Agios.
- Market entry pathways increasingly involve collaborations, especially for companion diagnostics development.
2. Innovation & Pipeline Trends
- Focus on next-generation IDH1 inhibitors with improved selectivity and fewer side effects.
- Combination therapy pipelines integrating IDH1 inhibitors with immunotherapies or chemotherapies.
3. Regulatory & Policy Environment
- FDA and EMA increasingly approving molecularly targeted agents, with accelerated processes for breakthrough designations.
- Patent term extensions and data exclusivity underpin economic incentives.
4. Competitive Strategies
- Patent strategies including broad composition claims based on common scaffolds.
- Global patent filing campaigns in jurisdictions like US, Europe, Japan, and China.
- R&D investments to achieve therapeutic differentiation and broaden indications.
Comparative Analysis of Existing IDH1 Inhibitors and Patent Coverage
| Parameter | Ivosidenib (Tibsovo) | AG-120 (Vorasidenib) | AG-881 (Corcalenib) | Key Patent(s) Covered |
|---|---|---|---|---|
| Approval Year | 2018 | Under clinical trials | Preclinical/ Phase I | Composition, method of use |
| Indications | AML, cholangiocarcinoma | AML, gliomas | Gliomas, other solid tumors | Composition, combination patents |
| Patent Expiry | 2034–2038 | 2035–2039 | 2033–2037 | Compound structures, use patents |
| Geographical Patent Coverage | US, EU, JAPAN, CN | US, EU, JP | US, EU, CN | Broad coverage with extensions |
How Do Patent Trends and Market Dynamics Compare to Similar Oncology Targets?
| Criteria | IDH1 Inhibitors | EGFR Inhibitors | ALK Inhibitors |
|---|---|---|---|
| Market Maturity | Emerging | Mature | Growing, with many approved drugs |
| Number of Patents | Growing, incremental patents | Extensive patent portfolios | Extensive patent landscape |
| Innovation Rate | Moderate, focus on next-gen agents | High, combination strategies emerging | Moderate, resistance management |
| Regulatory Environment | Supportive, accelerated approvals | Well-established | Variable, depending on indication |
Future Outlook and Strategic Implications
- Market Expansion: Increasing usage in gliomas and solid tumors, supported by biomarker-driven diagnostics.
- Patent Lifecycles: Expect patent expirations around 2034–2040, opening opportunities for generics or biosimilars.
- Innovation Potential: Development of combination therapies and next-generation inhibitors provides a competitive advantage.
- Global Patent Strategies: Key to securing manufacturing and market exclusivity across major jurisdictions.
Key Takeaways
- The IDH1 inhibitor market is characterized by strong initial growth, driven by targeted gene mutations in cancers, particularly AML and gliomas.
- Patent protection remains robust with foundational patents expiring mid-2030s; ongoing innovation and patent filings aim to extend market exclusivity.
- Leading companies like Bristol-Myers Squibb and Agios hold core patents, with licensing and collaborative agreements shaping market access.
- Clinical advancement toward combination therapies and new indications presents promising growth avenues.
- Global patent landscapes favor strategic filings in US, EU, Japan, and China, with potential challenges from patent challenges or emerging generic players.
- The regulatory environment favors innovators with expedited pathways, but patent expiry may introduce market competition around the late 2030s.
FAQs
Q1: What are the primary indications for IDH1 inhibitors?
They are predominantly indicated for IDH1-mutated acute myeloid leukemia (AML) and certain cholangiocarcinomas, with expanding research in gliomas.
Q2: Who are the leading patent holders in the IDH1 inhibitor space?
Celgene/Bristol-Myers Squibb, Agios Pharmaceuticals, and Novartis are the primary patent holders with extensive patent filings.
Q3: When are key patents for IDH1 inhibitors expected to expire?
Most foundational patents are projected to expire between 2034 and 2038, with licensing and secondary patents extending exclusivity.
Q4: How does the patent landscape impact market competition?
Strong patent protection enables market exclusivity for key players; patent expirations may lead to increased competition and generics.
Q5: What are future innovation trends in IDH1 inhibitors?
Focus is shifting towards next-generation inhibitors with improved safety profiles, combination therapies, and broader indications.
References
[1] Global Cancer Incidence and Mortality Data (2020)
[2] FDA Approvals of IDH1 Inhibitors (2018–2022)
[3] Patent Databases: USPTO, EPO, WIPO filings (2012–2022)
[4] Clinical Trial Registry (clinicaltrials.gov)
[5] Market Reports: Global Oncology Drugs Market (2021), IDH1 Inhibitor Market Forecasts
Note: This review synthesizes publicly available data and industry reports to provide an actionable insight into the IDH1 inhibitor market and patent landscape for strategic decision-making.
More… ↓
